CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...
- Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway “Dysregulated activation of the complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback